Observed survival rates for patients with TA-TMA among different risk groups
| Risk group . | Risk score . | n (%) . | 6-mo survival/death, n/n . | 6-mo survival rate, % . |
|---|---|---|---|---|
| Total cohort (N = 507) | ||||
| Low risk | 0-1 | 158 (31.1) | 136/22 | 86.1 |
| Intermediate risk | 2-3 | 229 (45.2) | 123/106 | 53.7 |
| High risk | 4-5 | 120 (23.7) | 25/95 | 20.8 |
| Derivation cohort (n = 269) | ||||
| Low risk | 0-1 | 83 (30.9) | 72/11 | 86.7 |
| Intermediate risk | 2-3 | 130 (48.3) | 66/64 | 50.8 |
| High risk | 4-5 | 56 (20.8) | 6/50 | 10.7 |
| Validation cohort (n = 238) | ||||
| Low risk | 0-1 | 75 (31.5) | 64/11 | 85.3 |
| Intermediate risk | 2-3 | 99 (41.6) | 57/42 | 57.6 |
| High risk | 4-5 | 64 (26.9) | 19/45 | 29.7 |
| Risk group . | Risk score . | n (%) . | 6-mo survival/death, n/n . | 6-mo survival rate, % . |
|---|---|---|---|---|
| Total cohort (N = 507) | ||||
| Low risk | 0-1 | 158 (31.1) | 136/22 | 86.1 |
| Intermediate risk | 2-3 | 229 (45.2) | 123/106 | 53.7 |
| High risk | 4-5 | 120 (23.7) | 25/95 | 20.8 |
| Derivation cohort (n = 269) | ||||
| Low risk | 0-1 | 83 (30.9) | 72/11 | 86.7 |
| Intermediate risk | 2-3 | 130 (48.3) | 66/64 | 50.8 |
| High risk | 4-5 | 56 (20.8) | 6/50 | 10.7 |
| Validation cohort (n = 238) | ||||
| Low risk | 0-1 | 75 (31.5) | 64/11 | 85.3 |
| Intermediate risk | 2-3 | 99 (41.6) | 57/42 | 57.6 |
| High risk | 4-5 | 64 (26.9) | 19/45 | 29.7 |